Pharmacokinetics of oral vitamin C

Steve Hickey, H. J. Roberts, N. Miller
{"title":"Pharmacokinetics of oral vitamin C","authors":"Steve Hickey, H. J. Roberts, N. Miller","doi":"10.1080/13590840802305423","DOIUrl":null,"url":null,"abstract":"Purpose . To test whether plasma vitamin C levels, following oral doses in supplemented volunteers, are tightly controlled and subject to a maximum in the region of 220 mML 21 , as suggested by previous researchers for depleted subjects. To determine plasma levels following single, variable-sized doses of standard and liposomal formulations of vitamin C and compare the effects of the different formulations. To determine whether plasma levels above ,280 mML 21 , which have selectively killed cancer, bacteria or viruses (in laboratory experiments), can be achieved using oral doses of vitamin C. Design . This was a single blind study, measuring plasma levels in two subjects, in samples taken halfhourly or hourly for 6 hours, following ingestion of vitamin C. Data were compared with published results and with data from 10 years of laboratory plasma determinations. Materials and methods . Standard 1 gram tablets of vitamin C; liposomal vitamin C. Plasma levels were analysed using the method of Butts and Mulvihill. Results . Preliminary investigations of the effects of liposomal and standard formulation ascorbate showed that blood plasma levels in excess of the previously assumed maximum of 220 mML 21 are possible. Large oral doses of liposomal ascorbate resulted in plasma levels above 400 mML 21 . Conclusions . Since a single oral dose can produce plasma levels in excess of 400 mML 21 , pharmacokinetic theory suggests that repeated doses could sustain levels well above the formerly assumed maximum. These results have implications for the use of ascorbate, as a nutrient and as a drug. For example, a short in vitro treatment of human Burkitt’s lymphoma cells with ascorbate, at 400 mML 21 , has been shown to result in ,50% cancer cell death. Using frequent oral doses, an equivalent plasma level could be sustained indefinitely. Thus, oral vitamin C has potential for use as a non-toxic, sustainable, therapeutic agent. Further research into the experimental and therapeutic aspects of high, frequent, oral doses of ascorbic acid either alone or (for cancer therapy) in combination with synergistic substances, such as alpha-lipoic acid, copper or vitamin K3, is needed urgently.","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"17 1","pages":"169-177"},"PeriodicalIF":0.0000,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590840802305423","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nutritional & environmental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/13590840802305423","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 31

Abstract

Purpose . To test whether plasma vitamin C levels, following oral doses in supplemented volunteers, are tightly controlled and subject to a maximum in the region of 220 mML 21 , as suggested by previous researchers for depleted subjects. To determine plasma levels following single, variable-sized doses of standard and liposomal formulations of vitamin C and compare the effects of the different formulations. To determine whether plasma levels above ,280 mML 21 , which have selectively killed cancer, bacteria or viruses (in laboratory experiments), can be achieved using oral doses of vitamin C. Design . This was a single blind study, measuring plasma levels in two subjects, in samples taken halfhourly or hourly for 6 hours, following ingestion of vitamin C. Data were compared with published results and with data from 10 years of laboratory plasma determinations. Materials and methods . Standard 1 gram tablets of vitamin C; liposomal vitamin C. Plasma levels were analysed using the method of Butts and Mulvihill. Results . Preliminary investigations of the effects of liposomal and standard formulation ascorbate showed that blood plasma levels in excess of the previously assumed maximum of 220 mML 21 are possible. Large oral doses of liposomal ascorbate resulted in plasma levels above 400 mML 21 . Conclusions . Since a single oral dose can produce plasma levels in excess of 400 mML 21 , pharmacokinetic theory suggests that repeated doses could sustain levels well above the formerly assumed maximum. These results have implications for the use of ascorbate, as a nutrient and as a drug. For example, a short in vitro treatment of human Burkitt’s lymphoma cells with ascorbate, at 400 mML 21 , has been shown to result in ,50% cancer cell death. Using frequent oral doses, an equivalent plasma level could be sustained indefinitely. Thus, oral vitamin C has potential for use as a non-toxic, sustainable, therapeutic agent. Further research into the experimental and therapeutic aspects of high, frequent, oral doses of ascorbic acid either alone or (for cancer therapy) in combination with synergistic substances, such as alpha-lipoic acid, copper or vitamin K3, is needed urgently.
口服维生素C的药代动力学
目的。为了测试志愿者口服维生素C后血浆维生素C水平是否受到严格控制,并如先前研究人员建议的那样,将其控制在220 mML 21的最大值。测定单剂量、可变剂量维生素C标准制剂和脂质体制剂后的血浆水平,并比较不同制剂的效果。为了确定口服剂量的维生素c是否可以达到(在实验室实验中)选择性杀死癌症、细菌或病毒的280mml 21以上的血浆水平。这是一项单盲研究,测量两名受试者的血浆水平,在摄入维生素c后半小时或6小时内每小时采集一次样本。数据与已发表的结果和10年的实验室血浆测定数据进行了比较。材料和方法。标准1克维生素C片剂;采用Butts和Mulvihill法分析血浆中维生素c含量。结果。对脂质体和标准配方抗坏血酸影响的初步调查表明,血浆中抗坏血酸水平可能超过先前假设的220毫升21的最大值。大剂量口服抗坏血酸脂质体导致血浆水平高于400mml 21。结论。由于单次口服剂量可产生超过400mml的血浆水平21,药代动力学理论表明,多次给药可维持远高于先前假定的最大值的水平。这些结果对抗坏血酸作为一种营养物质和药物的使用具有启示意义。例如,抗坏血酸对人类伯基特淋巴瘤细胞进行短期体外治疗,剂量为400mml 21,已被证明可导致50%的癌细胞死亡。使用频繁的口服剂量,等效的血浆水平可以无限期维持。因此,口服维生素C有可能作为一种无毒、可持续的治疗剂使用。迫切需要进一步研究高剂量、频繁口服抗坏血酸单独使用或(用于癌症治疗)与α -硫辛酸、铜或维生素K3等协同物质联合使用的实验和治疗方面的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信